Anagram Therapeutics

About Anagram Therapeutics

Anagram Therapeutics is a biopharmaceutical company dedicated to developing breakthrough orally-delivered enzyme therapies for rare, life-threatening diseases, specifically targeting Malabsorption Syndromes and Nutrient Metabolism Disorders. Inspired by the patients they aim to help, their mission is to realign expectations, reimagine treatments, and rethink possibilities to improve the lives of infants, children, adults, and their families affected by these conditions.

Products & Services

ANG003:A new class of enzyme replacement therapy for exocrine pancreatic insufficiency and malabsorption syndromes, offering broad-spectrum composition (lipase for fat, protease for protein, amylase for carbohydrate) to make a life-changing impact for those requiring oral ERT. Currently in Phase 3.

ANG011:Engineered for Congenital Malabsorptive Syndrome to break down specific carbohydrates due to enzyme deficiencies, aiming to avoid severe complications associated with carbohydrate malabsorption. Currently in preclinical stage.

Specialties

Orally-delivered enzyme therapeutics Malabsorption Syndromes Nutrient Metabolism Disorders Enzyme replacement therapy Gastrointestinal physiology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant/Non-equity Funding T: - FT: Grant/Non-equity Funding	A: 15500000 MR: - FA: $15.5 million FAN: 15500000	D: 2023-04-04 FD: 2023-04-04	1 investors

Grant/Non-equity Funding Latest

2023-04-04

$15.5M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert Gallotto

President and Chief Executive Officer of Anagram Therapeutics

D

David Brown

Chief of Technology Development

D

Don G. Burstyn

Senior Advisor in regulatory affairs and quality

M

Marcie Clarkin

Vice President of Clinical Strategic Operations

P

Pamela Nelson

Executive Vice President Regulatory Affairs

H

Hugh Wight

Chief, Corporate Development

View 10 more team members with Pro

Unlock Full Team Directory

Recent News